CL-218,872 EU

6 - 52 - 52

Discover CL-218,872 – The Next Generation Sedative

Esittelyssä CL-218,872, a groundbreaking sedative-hypnotic offering unparalleled efficacy in inducing sleep and reducing anxiety. Unlike traditional benzodiazepines, CL-218,872 targets specific GABA A receptors, ensuring a focused approach with fewer side effects. Ideal for research and therapeutic applications, it’s a beacon of hope for those seeking reliable and safe sedation.

Tämä tuote on saatavana myös Kapselit ja Pisarat helpompaa tutkimusta varten.

Kaikki EU:n vähittäiskaupan tuotteet voidaan toimittaa vain EU-maihin.

Kaikki tällä verkkosivustolla myytävät muuntohuumeet on tarkoitettu tutkimukseen ja rikosteknisiin sovelluksiin.

 

Product Overview:

CL-218,872 is a novel sedative and hypnotic compound. Unlike traditional benzodiazepines, it belongs to a unique class of nonbenzodiazepine hypnotics. The compound is particularly noted for its selective action on the GABA A receptor, specifically targeting the α1 subtype.

Chemical and Pharmacological Properties:

The molecular structure of CL-218,872 differentiates it from benzodiazepines, contributing to its unique pharmacological profile. Its action as a partial agonist at the GABA A receptor sites leads to sedative, anxiolytic, anticonvulsant, and amnestic effects, with a reduced risk of dependency compared to traditional benzodiazepines.

Annostus ja antotapa:

The optimal dosage of CL-218,872 varies depending on the intended use and the subject’s physiology. In research settings, dosages are carefully controlled and monitored.

Therapeutic Effects:

CL-218,872 is primarily used in research for its sedative and hypnotic effects. It has shown potential in studies for inducing sleep and reducing anxiety, with a faster onset and shorter duration of action, making it advantageous for specific therapeutic applications.

Side Effects and Harm Reduction:

Like all sedative-hypnotics, CL-218,872 can cause side effects such as dizziness, confusion, and motor impairment. Long-term use or misuse can lead to tolerance and dependence. Its safety profile, however, indicates a lower risk of these adverse effects compared to traditional benzodiazepines. Harm reduction strategies involve controlled administration, monitoring for adverse reactions, and avoiding use with other central nervous system depressants.

Comparative Analysis:

In comparison to other hypnotics like triazolam or zolpidem, CL-218,872 offers a unique balance of efficacy and safety, making it a subject of interest in both pharmacological research and potential clinical use.

Miksi ostaa CL-218,872 EU from RECHEMCO?

★ Meillä on pitkä kauppahistoria markkinoilla, joten voit hyötyä kokemuksestamme.
★ CL-218,872 testattiin ja tarkistettiin.
★ We accept various payment methods such as Bitcoin, Monero, many other cryptocurrencies and bank wire.

Mitä saat ostaessasi CL-218,872 EU from RECHEMCO?

- Yksi suljettu alumiinifoliopussi, joka sisältää korkealuokkaisia CL-218,872 EU
• White powder
• 98-99% Purity

Määrä

50mg, 100mg, 250mg, 500mg, 1g.

Arvostelut

Arvosteluja ei vielä ole.

Kirjoita ensimmäinen tuotearvio tuotteelle "CL-218,872 EU"

Sähköpostiosoitettasi ei julkaista. Pakolliset kentät on merkitty *